- IceCure Medical Ltd. (NASDAQ: ICCM) missed Q1 2026 earnings and revenue estimates, reporting an EPS of -$0.06 against an estimated -$0.03 and revenue of $911 thousand below $1.34 million.
- Despite the overall miss, the medical device company saw revenue growth from $0.73 million year-over-year, primarily driven by increased ProSense® system sales in North America and a 46% rise in active customer accounts.
- While currently unprofitable with a negative P/E ratio of -1.13, IceCure Medical’s financial health remains stable, evidenced by a low debt-to-equity ratio of 0.02 and a strong current ratio of 2.61.
IceCure Medical Ltd. (NASDAQ: ICCM) is a leading medical device company specializing in tumor treatment. It develops the ProSense® system, an innovative cryoablation technology that uses extreme cold to destroy tumors in a minimally-invasive procedure. This advanced system has received crucial clearance from the U.S. Food and Drug Administration (FDA), bolstering IceCure Medical’s position in the market.
On May 12, 2026, IceCure Medical announced its first-quarter earnings results. The company reported an earnings per share of -$0.06. As highlighted by Zacks Investment Research, this missed the consensus estimate of -$0.03 per share. This Q1 earnings loss was double what analysts expected and matched the loss reported in the same quarter of the previous year, raising concerns about IceCure Medical’s profitability outlook.
IceCure Medical’s revenue performance also fell short of expectations. It posted revenue of $911 thousand, which was significantly below the analyst estimate of $1.34 million. This represents a substantial miss of nearly 55%. Over the last four quarters, the medical technology company has consistently been unable to surpass consensus estimates for either its earnings or its revenue, indicating a pattern in its financial performance.
Despite missing overall estimates, IceCure Medical’s total revenue did increase from $0.73 million a year ago. As highlighted by PR Newswire, this positive revenue growth is primarily driven by a substantial increase in ProSense® system sales in North America. The number of active customer accounts utilizing the innovative cryoablation system has grown by 46% since it received FDA clearance, showcasing strong market adoption for IceCure Medical’s core product.
IceCure Medical is currently unprofitable, reflected by a negative price-to-earnings (P/E) ratio of -1.13. A negative P/E ratio indicates that the company has negative earnings. However, its overall financial health appears stable with a low debt-to-equity ratio of 0.02 and a strong current ratio of 2.61, demonstrating its ability to cover short-term debts and manage its balance sheet effectively. These investment insights suggest a company with potential despite current unprofitability.
